Stephens & Co. Maintains Overweight on Apyx Medical, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst George Sellers has maintained an Overweight rating on Apyx Medical (NASDAQ:APYX) but has reduced the price target from $8 to $5.
November 10, 2023 | 3:44 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Stephens & Co. maintains an Overweight rating on Apyx Medical but lowers the price target from $8 to $5, indicating a potential downside compared to the previous target.
The reduction in price target by Stephens & Co. suggests that they see less upside potential for Apyx Medical's stock price in the short term, which could lead to negative investor sentiment and a potential decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100